Cansino Biologics Inc. (688185.SH): DTcP-Hib-MCV4 Combined Vaccine Initiates Phase I Clinical Trial and Completes First Subject Enrollment

Stock News12-19

Cansino Biologics Inc. (688185.SH) announced that its adsorbed acellular pertussis (component), diphtheria, tetanus, Haemophilus influenzae type b (conjugate), and ACYW135 meningococcal (conjugate) combined vaccine (referred to as the "DTcP-Hib-MCV4 Combined Vaccine") has officially initiated a Phase I clinical trial and completed the enrollment of the first subject. The Phase I trial is a randomized, partially blinded, dose-exploration, positive/placebo-controlled clinical study designed to evaluate the safety and immunogenicity of the DTcP-Hib-MCV4 Combined Vaccine in individuals aged 2 months to 6 years.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156930789?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156930789","market":"sh","top_or_hot":-1,"title":"Cansino Biologics Inc. (688185.SH): DTcP-Hib-MCV4 Combined Vaccine Initiates Phase I Clinical Trial and Completes First Subject Enrollment","media":"Stock News","content":"<p>Cansino Biologics Inc. (688185.SH) announced that its adsorbed acellular pertussis (component), diphtheria, tetanus, Haemophilus influenzae type b (conjugate), and ACYW135 meningococcal (conjugate) combined vaccine (referred to as the \"DTcP-Hib-MCV4 Combined Vaccine\") has officially initiated a Phase I clinical trial and completed the enrollment of the first subject. The Phase I trial is a randomized, partially blinded, dose-exploration, positive/placebo-controlled clinical study designed to evaluate the safety and immunogenicity of the DTcP-Hib-MCV4 Combined Vaccine in individuals aged 2 months to 6 years.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cansino Biologics Inc. (688185.SH): DTcP-Hib-MCV4 Combined Vaccine Initiates Phase I Clinical Trial and Completes First Subject Enrollment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCansino Biologics Inc. (688185.SH): DTcP-Hib-MCV4 Combined Vaccine Initiates Phase I Clinical Trial and Completes First Subject Enrollment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-19 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cansino Biologics Inc. (688185.SH) announced that its adsorbed acellular pertussis (component), diphtheria, tetanus, Haemophilus influenzae type b (conjugate), and ACYW135 meningococcal (conjugate) combined vaccine (referred to as the \"DTcP-Hib-MCV4 Combined Vaccine\") has officially initiated a Phase I clinical trial and completed the enrollment of the first subject. The Phase I trial is a randomized, partially blinded, dose-exploration, positive/placebo-controlled clinical study designed to evaluate the safety and immunogenicity of the DTcP-Hib-MCV4 Combined Vaccine in individuals aged 2 months to 6 years.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688185","symbol_name":"康希诺","start_time":0,"source_url":"","article_id":"1156930789","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156930789","pubTimestamp":1766133623,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Cansino Biologics Inc. (688185.SH) announced that its adsorbed acellular pertussis (component), diphtheria, tetanus, Haemophilus influenzae type b (conjugate), and ACYW135 meningococcal (conjugate)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688185":"康希诺","BK0239":"医药制造"},"translate_title":"康希诺生物股份公司（688185.SH）：DTcP-Hib-MCV4联合疫苗启动I期临床试验并完成首例受试者入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688185":1},"content_text":"Cansino Biologics Inc. (688185.SH) announced that its adsorbed acellular pertussis (component), diphtheria, tetanus, Haemophilus influenzae type b (conjugate), and ACYW135 meningococcal (conjugate) combined vaccine (referred to as the \"DTcP-Hib-MCV4 Combined Vaccine\") has officially initiated a Phase I clinical trial and completed the enrollment of the first subject. The Phase I trial is a randomized, partially blinded, dose-exploration, positive/placebo-controlled clinical study designed to evaluate the safety and immunogenicity of the DTcP-Hib-MCV4 Combined Vaccine in individuals aged 2 months to 6 years.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156930789","isCrawlerRequest":true}